Developer docs
API playgroundTry for free, no card

Search company profiles

Gemelli Biotech

Full company profile

uuid0000rdu

Namestring
Gemelli Biotech
Legal namestring
Gemelli Biotech Corp.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Gemelli Biotech is a US-based precision diagnostics company that develops and commercializes at-home clinical tests for gastrointestinal diseases, primarily SIBO (Small Intestinal Bacterial Overgrowth), IMO (Intestinal Methanogen Overgrowth), ISO (Intestinal Sulfide Overproduction), and post-infectious IBS (PI-IBS). The company was founded in 2018 and is headquartered in Raleigh, North Carolina, with research and product co-development rooted in Cedars-Sinai's Medically Associated Science and Technology (MAST) Program, where the underlying biomarker science originated.

The company's product line consists of two core tests. Trio-Smart is a Laboratory Developed Test (LDT) conducted at a CLIA-certified lab that uses an at-home breath collection device to measure three fermented gases (hydrogen, methane, and hydrogen sulfide), distinguishing it from conventional two-gas breath tests with a stated 20x sensitivity advantage. IBS-Smart is an at-home capillary blood test (collected via a Tasso device) that measures anti-CdtB and anti-vinculin antibodies with a stated positive predictive value of 96-100% for diagnosing post-infectious IBS. A Trio-Smart Malabsorption variant extends the breath test to lactose, fructose, and sucrose intolerance. Both core products require a valid prescription from a licensed healthcare provider.

Gemelli generates revenue through one-time sales of at-home collection kits ordered via direct-to-consumer e-commerce websites, through healthcare provider ordering channels, and via third-party telehealth and fulfillment partners who facilitate prescription processing. The company claims a cumulative user base of over 100,000 patients and physicians, and counts Johns Hopkins, Stanford, UCLA, Yale, and Sutter Health among named adopters. The company has raised approximately $28.35M in cumulative funding across seed, early, and Series A rounds (Series A of $19M led by Blue Ox Healthcare Partners in June 2022), is privately held, and operates with 11-50 employees.

Short descriptiontext

Gemelli Biotech is a US-based precision diagnostics company that develops and sells at-home clinical tests for gastrointestinal conditions including SIBO, IMO, ISO, and post-infectious IBS, serving patients with chronic gut symptoms and prescribing gastroenterologists and GI clinics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRaleigh, United States
HQ citystring
Raleigh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gastrointestinal diagnostic tests, at-home breath testing, microbiome diagnostics, IBS blood testing, SIBO diagnostic kits
Industry2 codes
PRIMARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
SECONDARYHLAHAOAK
Home-Use & OTC Rapid Self-Tests (Consumer POCT kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Gastrointestinal Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Test Sales
TypeOne Time License
Description

One-time sale of at-home collection kits (breath tests and blood tests) ordered by patients with a valid prescription from a licensed healthcare provider. Tests are processed at CLIA-certified labs.

gemellibiotech.com
2Provider/Prescriber Orders
TypeOne Time License
Description

Healthcare providers order collection kits to ship to their offices or directly to patients. Fulfillment handled through independent third-party medical providers and fulfillment partners.

gemellibiotech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 2 records shown
1Trio-Smart
Description

A 3-gas breath test for identifying SIBO, IMO, and ISO by measuring hydrogen, methane, and hydrogen sulfide.

gemellibiotech.com
+1 more record
Core offering1 text field

Gemelli Biotech develops and sells at-home precision diagnostic test kits for gastrointestinal diseases, primarily the Trio-Smart 3-gas breath test for SIBO, IMO, and ISO and the IBS-Smart blood test for post-infectious IBS. Tests are self-collected at home, shipped to CLIA-certified laboratories, and produce results delivered electronically within 2-5 business days.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 20x more sensitive than conventional breath tests
+3 more records
Product overview1 text field

Gemelli Biotech offers two core at-home GI diagnostic test products: Trio-Smart, a 3-gas breath test that measures hydrogen, methane, and hydrogen sulfide to diagnose SIBO, IMO, and ISO; and IBS-Smart, a blood test that detects anti-CdtB and anti-vinculin antibodies to diagnose post-infectious IBS. Trio-Smart also has a malabsorption variant for testing lactose, fructose, and sucrose intolerance. Both tests are ordered online, collected at home, and shipped to CLIA-certified labs for processing with results delivered electronically.

Product and service3 records
1Trio-Smart
CategoryAt-home breath diagnostic test
Description

At-home 3-gas breath test that measures hydrogen, methane, and hydrogen sulfide to identify SIBO (Small Intestinal Bacterial Overgrowth), IMO (Intestinal Methanogen Overgrowth), and ISO (Intestinal Sulfide Overproduction). Breath samples are self-collected at home and shipped to a CLIA-certified lab for analysis, with results delivered within 2-5 business days. Reported to be 20x more sensitive than conventional breath tests and used by over 100,000 patients and physicians.

2Trio-Smart Malabsorption Test
CategoryAt-home breath diagnostic test
Description

A variant of the Trio-Smart breath test that screens for carbohydrate malabsorption, including lactose, fructose, and sucrose intolerance, using the same at-home breath collection methodology.

3IBS-Smart
CategoryAt-home blood diagnostic test
Description

At-home capillary blood test that measures anti-CdtB and anti-vinculin antibodies to diagnose Post-Infectious IBS (PI-IBS). Uses the Tasso device for virtually painless at-home capillary blood collection, with a reported positive predictive value of 96% to 100% and results delivered within 2-5 business days.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-22
Description

Founding investor and strategic partner through the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai. Co-developed IBS-Smart and supports ongoing innovation. Provides early access to microbiome research discoveries.

Strategic tierSupportingTypeTechnology or Integration
Description

Provides the Tasso device used in the IBS-Smart kit for at-home capillary blood collection. Enables convenient, virtually painless blood sampling without needles or phlebotomy visits.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct peer offering SIBO and IMO breath testing diagnostic services to clinicians and patients. Highly comparable in product category (GI breath testing) and clinical customer base, though historically focused on 2-gas rather than 3-gas measurement.

TypeDirect peer
Description

Specialty clinical laboratory offering GI diagnostics including SIBO breath tests and stool-based microbiome assessments. Directly comparable as a specialty diagnostics lab serving functional/holistic GI clinicians with similar test menu and patient population.

TypeDirect peer
Description

Specialty reference lab providing SIBO breath testing and comprehensive stool analysis for clinicians treating functional GI disorders. Closely comparable reference lab model and prescriber channel.

4Aerodiagnostics
TypeDirect peer
Description

Breath testing laboratory focused on SIBO, IMO, and lactose intolerance. Direct peer in the same GI breath testing category with overlapping patient and prescriber audiences.

TypeBroad incumbent
Description

Established specialty GI diagnostics company (now part of Nestlé Health Science) offering IBD, IBS, and celiac serology/antibody testing. Comparable specialty GI diagnostics focus with broader portfolio and institutional presence.

TypeEmerging player
Description

D2C microbiome and gut health testing company using stool-based RNA analysis for personalized recommendations. Comparable as a consumer-facing gut diagnostics brand, though uses different underlying technology (metatranscriptomics).

TypeEmerging player
Description

Health and wellness testing brand offering gut microbiome and wellness panels to consumers and practitioners. Comparable D2C gut diagnostics positioning with practitioner channel overlap.

TypeBroad incumbent
Description

Subsidiary of bioMérieux offering multiplex molecular GI pathogen panels (FilmArray). Comparable GI diagnostics focus at higher-incidence infection end of spectrum, well-capitalized incumbent.

TypeOthers
Description

Provider of the at-home capillary blood collection device used in Gemelli's IBS-Smart kit. Adjacent technology partner rather than competitor; relevant comparably for at-home diagnostic device economics.

TypeBroad incumbent
Description

Specialty diagnostic services now under Quest, historically built a specialty-test channel to clinicians that mirrors Gemelli's prescriber-driven model. Relevant comparable for scaling a specialty assay through clinician adoption before eventual acquisition or platform integration.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gemelli Biotech

Gastrointestinal Diagnosticsgemellibiotech.com

Gemelli Biotech is a US-based precision diagnostics company that develops and sells at-home clinical tests for gastrointestinal conditions including SIBO, IMO, ISO, and post-infectious IBS, serving patients with chronic gut symptoms and prescribing gastroenterologists and GI clinics.

What Gemelli Biotech does

Gemelli Biotech is a US-based precision diagnostics company that develops and commercializes at-home clinical tests for gastrointestinal diseases, primarily SIBO (Small Intestinal Bacterial Overgrowth), IMO (Intestinal Methanogen Overgrowth), ISO (Intestinal Sulfide Overproduction), and post-infectious IBS (PI-IBS). The company was founded in 2018 and is headquartered in Raleigh, North Carolina, with research and product co-development rooted in Cedars-Sinai's Medically Associated Science and Technology (MAST) Program, where the underlying biomarker science originated.

The company's product line consists of two core tests. Trio-Smart is a Laboratory Developed Test (LDT) conducted at a CLIA-certified lab that uses an at-home breath collection device to measure three fermented gases (hydrogen, methane, and hydrogen sulfide), distinguishing it from conventional two-gas breath tests with a stated 20x sensitivity advantage. IBS-Smart is an at-home capillary blood test (collected via a Tasso device) that measures anti-CdtB and anti-vinculin antibodies with a stated positive predictive value of 96-100% for diagnosing post-infectious IBS. A Trio-Smart Malabsorption variant extends the breath test to lactose, fructose, and sucrose intolerance. Both core products require a valid prescription from a licensed healthcare provider.

Gemelli generates revenue through one-time sales of at-home collection kits ordered via direct-to-consumer e-commerce websites, through healthcare provider ordering channels, and via third-party telehealth and fulfillment partners who facilitate prescription processing. The company claims a cumulative user base of over 100,000 patients and physicians, and counts Johns Hopkins, Stanford, UCLA, Yale, and Sutter Health among named adopters. The company has raised approximately $28.35M in cumulative funding across seed, early, and Series A rounds (Series A of $19M led by Blue Ox Healthcare Partners in June 2022), is privately held, and operates with 11-50 employees.

Gemelli Biotech firmographics

Firmographics
Name
Gemelli Biotech
Legal name
Gemelli Biotech Corp.
Website
https://gemellibiotech.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Gemelli Biotech is a US-based precision diagnostics company that develops and sells at-home clinical tests for gastrointestinal conditions including SIBO, IMO, ISO, and post-infectious IBS, serving patients with chronic gut symptoms and prescribing gastroenterologists and GI clinics.
Ownership category
akta.pro rank

Gemelli Biotech industry classification

Industry
Product category
Gastrointestinal Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAFAH
Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal)
SECONDARYHLAHAOAK
Home-Use & OTC Rapid Self-Tests (Consumer POCT kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics

Keywords

  • Gastrointestinal diagnostic tests
  • At-home breath testing
  • Microbiome diagnostics
  • IBS blood testing
  • SIBO diagnostic kits

Where Gemelli Biotech is headquartered

Location

Headquarters

HQ city
Raleigh
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Gemelli Biotech business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Diagnostic Test Sales: One-time sale of at-home collection kits (breath tests and blood tests) ordered by patients with a valid prescription from a licensed healthcare provider. Tests are processed at CLIA-certified labs.
  2. Provider/Prescriber Orders: Healthcare providers order collection kits to ship to their offices or directly to patients. Fulfillment handled through independent third-party medical providers and fulfillment partners.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Gemelli Biotech product offering

Product offering

Core offering

Gemelli Biotech develops and sells at-home precision diagnostic test kits for gastrointestinal diseases, primarily the Trio-Smart 3-gas breath test for SIBO, IMO, and ISO and the IBS-Smart blood test for post-infectious IBS. Tests are self-collected at home, shipped to CLIA-certified laboratories, and produce results delivered electronically within 2-5 business days.

Product overview

Gemelli Biotech offers two core at-home GI diagnostic test products: Trio-Smart, a 3-gas breath test that measures hydrogen, methane, and hydrogen sulfide to diagnose SIBO, IMO, and ISO; and IBS-Smart, a blood test that detects anti-CdtB and anti-vinculin antibodies to diagnose post-infectious IBS. Trio-Smart also has a malabsorption variant for testing lactose, fructose, and sucrose intolerance. Both tests are ordered online, collected at home, and shipped to CLIA-certified labs for processing with results delivered electronically.

Differentiator

Problem solved

Functional benefit

Brands

  • Trio-Smart: A 3-gas breath test for identifying SIBO, IMO, and ISO by measuring hydrogen, methane, and hydrogen sulfide.
  • IBS-Smart

Products and services

  • Trio-Smart At-home 3-gas breath test that measures hydrogen, methane, and hydrogen sulfide to identify SIBO (Small Intestinal Bacterial Overgrowth), IMO (Intestinal Methanogen Overgrowth), and ISO (Intestinal Sulfide Overproduction). Breath samples are self-collected at home and shipped to a CLIA-certified lab for analysis, with results delivered within 2-5 business days. Reported to be 20x more sensitive than conventional breath tests and used by over 100,000 patients and physicians.
  • Trio-Smart Malabsorption Test A variant of the Trio-Smart breath test that screens for carbohydrate malabsorption, including lactose, fructose, and sucrose intolerance, using the same at-home breath collection methodology.
  • IBS-Smart At-home capillary blood test that measures anti-CdtB and anti-vinculin antibodies to diagnose Post-Infectious IBS (PI-IBS). Uses the Tasso device for virtually painless at-home capillary blood collection, with a reported positive predictive value of 96% to 100% and results delivered within 2-5 business days.

Quantifiable outcome

  • 20x more sensitive than conventional breath tests
  • +3 more outcomes

Companies that use Gemelli Biotech

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Gemelli Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Gemelli Biotech partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and supporting.

  • Cedars-SinaicoreStrategic or Co-development Partner · 22 June 2022Founding investor and strategic partner through the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai. Co-developed IBS-Smart and supports ongoing innovation. Provides early access to microbiome research discoveries.
  • TassosupportingTechnology or IntegrationProvides the Tasso device used in the IBS-Smart kit for at-home capillary blood collection. Enables convenient, virtually painless blood sampling without needles or phlebotomy visits.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Gemelli Biotech competitors and assessment

Company assessment

Direct peers

  • Commonwealth Diagnostics International: Direct peer offering SIBO and IMO breath testing diagnostic services to clinicians and patients. Highly comparable in product category (GI breath testing) and clinical customer base, though historically focused on 2-gas rather than 3-gas measurement.
  • Genova Diagnostics: Specialty clinical laboratory offering GI diagnostics including SIBO breath tests and stool-based microbiome assessments. Directly comparable as a specialty diagnostics lab serving functional/holistic GI clinicians with similar test menu and patient population.
  • Doctor's Data: Specialty reference lab providing SIBO breath testing and comprehensive stool analysis for clinicians treating functional GI disorders. Closely comparable reference lab model and prescriber channel.
  • Aerodiagnostics: Breath testing laboratory focused on SIBO, IMO, and lactose intolerance. Direct peer in the same GI breath testing category with overlapping patient and prescriber audiences.

Broad incumbents

  • Prometheus Laboratories: Established specialty GI diagnostics company (now part of Nestlé Health Science) offering IBD, IBS, and celiac serology/antibody testing. Comparable specialty GI diagnostics focus with broader portfolio and institutional presence.
  • BioFire Diagnostics: Subsidiary of bioMérieux offering multiplex molecular GI pathogen panels (FilmArray). Comparable GI diagnostics focus at higher-incidence infection end of spectrum, well-capitalized incumbent.
  • Cleveland HeartLab (now part of Quest Diagnostics): Specialty diagnostic services now under Quest, historically built a specialty-test channel to clinicians that mirrors Gemelli's prescriber-driven model. Relevant comparable for scaling a specialty assay through clinician adoption before eventual acquisition or platform integration.

Emerging players

  • Viome Life Sciences: D2C microbiome and gut health testing company using stool-based RNA analysis for personalized recommendations. Comparable as a consumer-facing gut diagnostics brand, though uses different underlying technology (metatranscriptomics).
  • Thorne (formerly Onegevity): Health and wellness testing brand offering gut microbiome and wellness panels to consumers and practitioners. Comparable D2C gut diagnostics positioning with practitioner channel overlap.

Others

  • Tasso: Provider of the at-home capillary blood collection device used in Gemelli's IBS-Smart kit. Adjacent technology partner rather than competitor; relevant comparably for at-home diagnostic device economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

Gemelli Biotech social profiles

Digital presence

Gemelli Biotech compliance and trust

Trust signal

Compliance1 record

Gemelli Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gemelli Biotech leadership team

Management profile

Number of profiles

Profiles12 records

Gemelli Biotech funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gemelli Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gemelli Biotech

What does Gemelli Biotech do?

Gemelli Biotech develops and sells at-home precision diagnostic test kits for gastrointestinal diseases, primarily the Trio-Smart 3-gas breath test for SIBO, IMO, and ISO and the IBS-Smart blood test for post-infectious IBS. Tests are self-collected at home, shipped to CLIA-certified laboratories, and produce results delivered electronically within 2-5 business days.

Is Gemelli Biotech a public or private company?

Gemelli Biotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Gemelli Biotech founded?

Gemelli Biotech was founded in 2018. It employs 11 to 50 people.

Where is Gemelli Biotech based?

Gemelli Biotech is headquartered in Raleigh, United States, in the North America region.

How does Gemelli Biotech make money?

Two revenue lines are on record. Diagnostic Test Sales are the primary driver. The others are provider/Prescriber Orders.

Who are Gemelli Biotech's main competitors?

Direct peers on record are Commonwealth Diagnostics International, Genova Diagnostics, Doctor's Data and Aerodiagnostics. Broad incumbents are Prometheus Laboratories, BioFire Diagnostics and Cleveland HeartLab (now part of Quest Diagnostics). Emerging players are Viome Life Sciences and Thorne (formerly Onegevity). Tasso is listed as an others.

Does Gemelli Biotech have an API?

No public API is recorded for Gemelli Biotech.

What industry is Gemelli Biotech in?

Gemelli Biotech's product category is Gastrointestinal Diagnostics. Its primary akta.pro industry code is HLAAAFAH, Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal), with a secondary code of HLAHAOAK, Home-Use & OTC Rapid Self-Tests (Consumer POCT kits). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogTechnology Behind Gemelli Biotech’s Trio-Smart® Used in New Study Linking Intestinal Sulfide Overproduction to a Distinct Small-Bowel Gene-Expression SignatureA study in mSystems found intestinal sulfide overproduction (ISO) has a distinct small-bowel gene-expression signature, differing from SIBO and IMO. The research, using Gemelli Biotech's gas chromatography, suggests treating these conditions as biologically interchangeable may overlook meaningful differences. The findings support individualized therapeutic strategies.FinancialContent Business PageTechnology Behind Gemelli Biotech’s Trio-Smart® Used in New Study Linking Intestinal Sulfide Overproduction to a Distinct Small-Bowel Gene-Expression SignatureA study in mSystems found that intestinal sulfide overproduction (ISO) shows a distinct small-bowel gene-expression signature, differing from SIBO and IMO. The analysis of 85 participants' biopsies showed ISO involved the broadest changes, including energy and immune genes. The findings support treating the three conditions separately.International Business TimesWhy Better Gut Health Care May Begin With More Precise Diagnostic DecisionsGemelli Biotech's at-home breath tests measure hydrogen, methane, and hydrogen sulfide to help diagnose IBS subtypes. A 2026 study found patients using these tests had lower diagnostic and office-visit costs. The company argues that better diagnostics should precede treatment, with clinicians and patients working together.FinancialContent Business PageReal-World IBS Study Links IBS-Smart® and Trio-Smart® Testing to Lower Use of Selected Diagnostic Procedures and Lower Captured Diagnostic CostsGemelli Biotech announced a real-world study published in Frontiers in Gastroenterology indicating that the use of its IBS-Smart and Trio-Smart tests reduced diagnostic procedures and costs for patients with suspected irritable bowel syndrome. The retrospective analysis of 219 U.S. patients showed significantly lower rates of colonoscopies and endoscopies, along with estimated cost savings of approximately $526 per patient for those receiving IBS-Smart. Researchers cautioned that while the observational data suggests more efficient diagnostic sequencing, prospective studies are needed to confirm sustained economic benefits.BioSpaceGemelli Biotech’s Trio-Smart® 3-Gas Breath Test and IBS-Smart® Blood Test, Featured Across Multiple Research Presentations at DDW 2026Gemelli Biotech will feature its Trio-Smart 3-gas breath test and IBS-Smart blood test in multiple research presentations at DDW 2026. The studies validate the accuracy and cost savings of first-line diagnosis for SIBO, PI-IBS, IMO, and ISO. The company expects to expand its work to help patients with these conditions.Salvo HealthSalvo Health & Gemelli Biotech partner to offer cutting-edge diagnostic testing for IBS and SIBO across 29 statesSalvo Health partnered with Gemelli Biotech to offer at-home GI diagnostic tests for SIBO, IMO, and post-infectious IBS across 29 U.S. states. The trio-smart breath test measures three gasses, and the ibs-smart blood test detects elevated antibodies, with the blood test available by early 2023.BioSpaceGemelli Biotech Completes $19 Million Series A FinancingGemelli Biotech completed a $19 million Series A financing led by Blue Ox Healthcare Partners, with Cedars-Sinai and others participating. The funds will accelerate commercialization of its trio-smart and ibs-smart diagnostic tests for IBS and SIBO, and expand sales and manufacturing capacity.FinSMEsGemelli Biotech Closes $19M Series A FinancingGemelli Biotech has closed a $19 million Series A funding round led by Blue Ox Healthcare Partners with participation from Cedars-Sinai and other investors. The company intends to utilize the capital to accelerate the commercialization of its precision diagnostic tests, trio-smart® and ibs-smart®, while expanding sales, marketing, and manufacturing operations in the United States.Venture Capital Access OnlineGemelli Biotech Completes $19 Million Series A FinancingGemelli Biotech Corp. completed a $19 million Series A financing round on June 22, 2022, to accelerate the commercialization of its precision diagnostic tests for gastrointestinal diseases. The funding will enable Gemelli to expand sales and marketing in the US and enhance its laboratory and manufacturing capabilities. The company has already launched new diagnostic tests aimed at improving the detection and treatment of conditions such as IBS and SIBO, impacting millions globally.BenzingaGemelli Biotech Completes $19 Million Series A FinancingGemelli Biotech Corp. has completed a $19 million Series A financing round aimed at commercializing its trio-smart® and ibs-smart® precision diagnostic tests for gastrointestinal diseases. The investment, led by Blue Ox Healthcare Partners, will also support the company's expansion of sales and marketing efforts within the U.S., as well as scaling laboratory and manufacturing operations in Raleigh and Los Angeles.